J
Jonathan A. Ledermann
Researcher at University College London
Publications - 332
Citations - 28241
Jonathan A. Ledermann is an academic researcher from University College London. The author has contributed to research in topics: Ovarian cancer & Olaparib. The author has an hindex of 65, co-authored 300 publications receiving 21862 citations. Previous affiliations of Jonathan A. Ledermann include University College London Hospitals NHS Foundation Trust & University College Hospital.
Papers
More filters
Journal ArticleDOI
Oxidation of Ovarian Epithelial Cancer Cells by Hypochlorous Acid Enhances Immunogenicity and Stimulates T Cells that Recognize Autologous Primary Tumor
Cheryl L-L. Chiang,Jonathan A. Ledermann,Egla Aitkens,Elizabeth Benjamin,David R. Katz,Benjamin M. Chain +5 more
TL;DR: Immunity with mature dendritic cells loaded with a generic oxidized tumor cell line stimulates a polyclonal antitumor response that recognizes autologous tumor, suggesting a new immunotherapeutic strategy to extend remission in ovarian cancer.
Journal ArticleDOI
British Gynaecological Cancer Society (BGCS) epithelial ovarian/fallopian tube/primary peritoneal cancer guidelines: recommendations for practice.
Christina Fotopoulou,Marcia Hall,Derek Cruickshank,Hani Gabra,Raji Ganesan,Cathy Hughes,Sean Kehoe,Jonathan A. Ledermann,Jo Morrison,Raj Naik,Phil Rolland,Sudha Sundar +11 more
TL;DR: The remit of this guideline is to collate and propose evidencebased guidelines for the management of epithelial ovarian-type cancers (ovary, fallopian tube or peritoneal origin) and borderline tumours.
Journal ArticleDOI
435 Candidate biomarkers of PARP inhibitor sensitivity in ovarian cancer beyond the BRCA genes
Darren Hodgson,B. Dougherty,Zhongwu Lai,L. Grinsted,S. Spencer,Mark J. O'Connor,Tony W. Ho,Jane Robertson,Jerry S. Lanchbury,Kirsten Timms,A. Gutin,M. Orr,H. Jones,B. Gilks,Chris Womack,James Sun,Roman Yelensky,Charlie Gourley,Jonathan A. Ledermann,J.C. Barrett +19 more
Journal ArticleDOI
Phase II randomized placebo-controlled study of olaparib (AZD2281) in patients with platinum-sensitive relapsed serous ovarian cancer (PSR SOC).
Jonathan A. Ledermann,P. Harter,Charlie Gourley,Michael Friedlander,Ignace Vergote,G. J. S. Rustin,Clare L. Scott,Werner Meier,Ronnie Shapira-Frommer,Tamar Safra,Daniela Matei,Euan Macpherson,Claire Watkins,J. Carmichael,Ursula A. Matulonis +14 more
TL;DR: In pts with PSR SOC, maintenance treatment with olaparib 400 mg bid provided a significant improvement in PFS, and toxicities were consistent with previous studies.
Journal ArticleDOI
Avelumab alone or in combination with pegylated liposomal doxorubicin versus pegylated liposomal doxorubicin alone in platinum-resistant or refractory epithelial ovarian cancer: Primary and biomarker analysis of the phase III JAVELIN Ovarian 200 trial
Eric Pujade-Lauraine,Keiichi Fujiwara,Jonathan A. Ledermann,Amit M. Oza,Rebecca Kristeleit,I.L. Ray-Coquard,Gary Richardson,Cristiana Sessa,Kan Yonemori,Susana Banerjee,Alexandra Leary,Anna V. Tinker,Kyung Hae Jung,Radoslaw Madry,Sang Yoon Park,Charles K. Anderson,Fabian Zohren,Ross A. Stewart,Caimiao Wei,Samuel S. Dychter,Bradley J. Monk +20 more